文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

经呼吸道给予预防性抗生素降低呼吸机相关性肺炎:随机对照试验的系统评价、网状Meta分析与试验序贯分析

Prophylactic Antibiotics Delivered Via the Respiratory Tract to Reduce Ventilator-Associated Pneumonia: A Systematic Review, Network Meta-Analysis, and Trial Sequential Analysis of Randomized Controlled Trials.
PubMed 文献 · Crit Care Med · 2024-05-09
一句话结论对机械通气超过48小时的成人,经呼吸道给予预防性抗生素可降低呼吸机相关性肺炎风险(RR 0.69),以雾化氨基糖苷类效果更明显。

该系统评价与网状Meta分析检索PubMed、Scopus、Cochrane图书馆和ClinicalTrials.gov截至2023年10月25日的英文研究,纳入7项随机对照试验共1445例机械通气超过48小时的成人患者,其中6项研究1283例使用雾化器给药。与对照组相比,经呼吸道给予预防性抗生素显著降低呼吸机相关性肺炎风险(RR 0.69,95%CI 0.53-0.89),亚组分析中氨基糖苷类(RR 0.67,95%CI 0.47-0.97)和雾化给药(RR 0.64,95%CI 0.49-0.83)效果更明显,而其他抗生素(头孢他啶和黏菌素)或气管内滴注未见相应效果。两组在死亡率、机械通气时间、ICU和住院时间、全身抗生素使用时间、气管切开需求及不良事件方面无显著差异,敏感性分析结果一致。

要点

  • 对机械通气超过48小时的成人,经呼吸道预防性使用抗生素使呼吸机相关性肺炎风险降低(RR 0.69,95%CI 0.53-0.89)。
  • 雾化氨基糖苷类亚组呼吸机相关性肺炎风险降低(RR 0.67,95%CI 0.47-0.97),雾化给药亚组RR 0.64(95%CI 0.49-0.83)。
  • 其他抗生素(头孢他啶和黏菌素)或气管内滴注未见显著降低呼吸机相关性肺炎风险。
  • 两组死亡率、机械通气时间、ICU和住院时间、全身抗生素使用时间、气管切开需求及不良事件无显著差异。
  • 共纳入7项随机对照试验1445例患者,其中6项研究1283例使用雾化器给药,敏感性分析结果一致。

适用人群与场景

  • 成人患者,机械通气超过48小时,接受雾化或滴注抗生素以预防呼吸机相关性肺炎,并设有对照组。

处置流程与药物剂量

  • 经呼吸道给予预防性抗生素:氨基糖苷类(RR 0.67,95%CI 0.47-0.97)或雾化给药(RR 0.64,95%CI 0.49-0.83)的亚组中呼吸机相关性肺炎风险降低更明显;其他抗生素(头孢他啶和黏菌素)或气管内滴注未见显著效果。

研究设计与关键结果

  • 系统评价、网状Meta分析与试验序贯分析,纳入7项随机对照试验共1445例机械通气超过48小时的成人患者,其中6项研究1283例使用雾化器给药。
  • 与对照组相比,经呼吸道给予预防性抗生素显著降低呼吸机相关性肺炎风险(RR 0.69,95%CI 0.53-0.89)。
  • 亚组分析:氨基糖苷类亚组呼吸机相关性肺炎风险RR 0.67(95%CI 0.47-0.97);雾化给药亚组RR 0.64(95%CI 0.49-0.83);其他抗生素(头孢他啶和黏菌素)或气管内滴注未见显著效果。
  • 两组死亡率、机械通气时间、ICU和住院时间、全身抗生素使用时间、气管切开需求及不良事件无显著差异。
  • 敏感性分析结果一致;纳入的随机对照试验主要结局未发现明显偏倚风险。

证据类型、等级与局限

  • 证据类型:随机对照试验的系统评价、网状Meta分析与试验序贯分析;采用GRADE方法评估证据质量。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对机械通气超过48小时的成人,经呼吸道给予预防性抗生素可降低呼吸机相关性肺炎风险,尤其雾化氨基糖苷类;但死亡率、机械通气时间、ICU和住院时间、全身抗生素使用时间、气管切开需求及不良事件无显著差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To assess the effects of antibiotics delivered via the respiratory tract in preventing ventilator-associated pneumonia (VAP).

DATA SOURCES: We searched PubMed, Scopus, the Cochrane Library, and ClinicalTrials.gov for studies published in English up to October 25, 2023.

STUDY SELECTION: Adult patients with mechanical ventilation of over 48 h and receiving inhaled or instilled antibiotics (with control group) to prevent VAP were included.

DATA EXTRACTION: Two independent groups screened studies, extracted the data, and assessed the risk of bias. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to assess the certainty/quality of the evidence. Results of a random-effects model were reported for overall and predefined subgroup meta-analyses. The analysis was primarily conducted on randomized controlled trials, and observational studies were used for sensitivity analyses.

DATA SYNTHESIS: Seven RCTs with 1445 patients were included, of which six involving 1283 patients used nebulizers to deliver antibiotics. No obvious risk of bias was found among the included RCTs for the primary outcome. Compared with control group, prophylactic antibiotics delivery via the respiratory tract significantly reduced the risk of VAP (risk ratio [RR], 0.69 [95% CI, 0.53-0.89]), particularly in subgroups where aminoglycosides (RR, 0.67 [0.47-0.97]) or nebulization (RR, 0.64 [0.49-0.83]) were used as opposed to other antibiotics (ceftazidime and colistin) or intratracheal instillation. No significant differences were observed in mortality, mechanical ventilation duration, ICU and hospital length of stay, duration of systemic antibiotics, need for tracheostomy, and adverse events between the two groups. Results were confirmed in sensitivity analyses.

CONCLUSIONS: In adult patients with mechanical ventilation for over 48 h, prophylactic antibiotics delivered via the respiratory tract reduced the risk of VAP, particularly for those treated with nebulized aminoglycosides.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Li J, Lyu S, Luo J, et al. Prophylactic Antibiotics Delivered Via the Respiratory Tract to Reduce Ventilator-Associated Pneumonia: A Systematic Review, Network Meta-Analysis, and Trial Sequential Analysis of Randomized Controlled Trials. Crit Care Med. 2024. PMID: 38722206. doi:10.1097/CCM.0000000000006323

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。